Search
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalTaurolidine is an antimicrobial used for the prevention of catheter-related infections. It is a derivative of the amino acid [taurine]. … and Antifungal Drugs (LPAD pathway) for the prevention of catheter-related bloodstream infections in a limited and specific patient population.
Metyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Tests for Pituitary FunctionNormethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitIt is marketed in Canada by Valeant under the tradename Cophylac.
Norflurane
go.drugbank.com/drugs/DB13116ApprovedInvestigationalWithdrawnNorflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).
Cloprednol
go.drugbank.com/drugs/DB13843InvestigationalCloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. [A31775,A31776]
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainEnlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigational[L63795] Elevated LDL-C is a principal modifiable risk factor for atherosclerotic cardiovascular disease, and cardiovascular outcomes trials have demonstrated that reducing LDL-C lowers the risk of … Across two 52-week placebo-controlled trials, enlicitide 20 mg once daily reduced LDL-C at Week 24 by 56% relative to placebo in patients with hypercholesterolemia at established or increased ASCVD risk
Cretostimogene grenadenorepvec
go.drugbank.com/drugs/DB05148InvestigationalCG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. … CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated in numerous preclinical studies.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalby the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved
NS-3728
go.drugbank.com/drugs/DB05835ExperimentalNS3728 is an orally active chloride channel blocker for the treatment of cancer.